{
    "nctId": "NCT03053193",
    "briefTitle": "MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles",
    "officialTitle": "MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 30000,
    "primaryOutcomeMeasure": "A large scale registry of full genome expression data to investigate new gene associations with prognostic and/or predictive value will be created.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage I, II, or III patients who receive MammaPrint, with or without BluePrint testing (male or female)\n* Informed consent form signed on the same day or before enrollment\n* New primary lesion\n\nExclusion Criteria:\n\n* Tumor sample shipped to Agendia with \u2264 30% tumor cells or that fails QA or QC criteria\n* Metastatic disease\n* Recurrent disease\n* Stage 0 disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}